Sarecycline: A review of preclinical and clinical evidence

Angela Yen Moore*, James Del Rosso, Jodi L. Johnson, Ayman Grada

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Sarecycline is a tetracycline-derived oral antibiotic, specifically designed for acne, and is approved by the Food and Drug Administration (FDA) in 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris (AV) in patients 9 years of age and older. It has been decades since a novel systemic antibiotic was approved to treat AV, a disease that affects up to 90% of teenagers and young adults worldwide and lasts well into adulthood. Sarecycline holds promise to yield fewer side effects than other commonly used broad-spectrum tetracyclines, including minocycline and doxycycline. The narrower spectrum of antibacterial activity of sarecycline, which specifically targets C. acnes and some Gram-positive bacteria with little or no activity against Gram-negative bacteria, suggests not only the potential for reduced emergence of antibiotic-resistant bacterial strains but also less disruption of the human gut microflora. Here, we review the key preclinical and clinical evidence on sarecycline.

Original languageEnglish (US)
Pages (from-to)553-560
Number of pages8
JournalClinical, Cosmetic and Investigational Dermatology
Volume13
DOIs
StatePublished - 2020

Keywords

  • Acne vulgaris
  • Antibiotic
  • Narrow spectrum
  • Sarecycline
  • Tetracycline

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Sarecycline: A review of preclinical and clinical evidence'. Together they form a unique fingerprint.

Cite this